Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's ...
GlobalData on MSN4mon
FDA hits Abbott FreeStyle Libre 3 recall with Class I tagThe FreeStyle Libre 3 reader and app are not affected. In a statement to Medical Device Network, an Abbott spokesperson said ...
Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results